Treatment of renal cell carcinoma with distant metastasis;Behandling av nyrekreft med fjernmetastaser

Tidsskrift for den Norske Laegeforening

Volumn 120, Issue 19, 2000, Pages 2274-2278

  Fossa S D ^a   Aass, N ^a   Tveter, K ^b   Dahl, O ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; CYTOSTATIC AGENT; FLUOROURACIL; GAMMA INTERFERON; PLACEBO; PREDNISONE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SHORT SURVEY; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; KIDNEY NEOPLASMS; NEPHRECTOMY; NORWAY; TONGUE NEOPLASMS;

EID: 0034692114     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (18)

1. Cancer in Norway 1996. Oslo: Kreftregisteret, 1999.
2. Oliver RT. Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol 1989; 63: 128-31.
3. Fosså SD, Kjølseth I, Lund G. Radiotherapy of metastases from renal cancer. Eur J Urol 1982; 8: 340-2.
4. Kjaer M. The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma. Cancer Treat Rev 1988; 15: 195-209.
5. Yagoda A. Chemotherapy of renal cell carcinoma: 1983-1989. Semin Urol 1989; 7: 199-206.
6. Pittman K, Selby P. The management of renal cell carcinoma. Crit Rev Oncol Hematol 1994; 16: 181-200.
7. Fosså SD, Martinelli G, Otto U, Schneider G, Wander H, Oberling F et al. Recombinant Interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center Phase-III study. Ann Oncol 1992; 3: 301-5.
8. Pyrhönen SO, Salminen EK, Ruutu M, Lehtonen T, Nurmi M, Tammela T et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859-67.
9. Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999; 353: 14-7.
10. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1265-71.
11. Negrier S, Escudier B, Lasset C, Douillard JY, Savary C, Chevreau C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1272-8.
12. Fosså SD, Aune H, Baggerud E, Granerud T, Heilo A, Theodorsen L. Continuous intravenous interleukin-2 infusion and subcutanous Interferon-α in metastatic renal cell carcinoma: worth to use in today's oncological routine practice? Eur J Cancer Oncol 1993; 9: 1313-5.
13. Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interferon-2b in advanced human malignancies. Lancet 1990; 335: 1509-12.
14. Dmitrovsky E, Bosl GJ. Active cancer therapy combining 13-cis-retinoic acid with interferon-alpha J Natl Cancer Inst 1992; 84: 218-9.
15. Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP et al. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumour activity in a phase-II trial and interactions in vitro. J Clin Oncol 1995; 13: 1950-7.
16. Motzer RJ, Murphy BA, Mazumdar M, Loehrer P, Wilding G, Schwartz L et al. Randomized phase III trial of interferon alfa-2A (IFN) versus IFN plus 13-cis-retinoic acid (CRA) in patients (pts) with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 1999 (suppl 330a): A 1271.
17. Fosså SD, Lehne G, Gunderson R, Hjelmaas U, Holdener EE. Recombinant interferon alfa-2A combined with prednisone in metastatic renal cell carcinoma: treatment results, serum interferon levels and the development of antibodies. Int J Cancer 1992; 50: 868-70.
18. Piga A, Bracci R, Ferretti B, Sandri P, Nortilli R, Acito L et al. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J Exp Clin Cancer Res 1998; 17: 213-7.